Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (Nasdaq: COO) is a global medical device company with two main business units, CooperVision and CooperSurgical, and its news flow reflects this mix of vision care and women’s health activities. Company press releases regularly provide updates on quarterly and annual financial results, including revenue, earnings per share, margins, and free cash flow, along with commentary from management on operational performance and priorities.
Investors following COO news will see detailed segment information for CooperVision and CooperSurgical, such as revenue by product category and geography, as well as explanations of non‑GAAP metrics, constant currency growth, and organic growth. Releases also describe reorganization and integration efforts, business optimization charges, and product line exits, offering context on how these actions affect reported margins and future cost structure.
CooperCompanies’ news also covers corporate governance and strategic topics. Recent announcements include changes in Board leadership, the appointment of new independent directors, and a formal strategic review of the company’s businesses, corporate structure, and capital allocation priorities. The company has disclosed cooperation agreements with investment partners and expansions of its share repurchase program, including a Board‑approved increase that brought total authorization to $2 billion.
In addition, CooperCompanies issues notices about upcoming earnings releases, conference calls, and participation in healthcare investment conferences, where senior executives present and answer questions. For those interested in the broader eye care landscape, external communications related to CooperVision highlight its role in contact lenses and myopia management. This news page brings together these financial, strategic, and industry‑related updates in one place for users tracking COO.
CooperCompanies (NYSE: COO) has appointed Nicholas Khadder as its new general counsel and corporate secretary, effective immediately. Khadder brings extensive legal experience, having previously served as general counsel at Standard BioTools Inc. from June 2016 to July 2022 and held several senior roles at Amyris, Inc. and other companies. He holds a Juris Doctor from Berkeley Law. This leadership change is expected to enhance the company's legal strategy and governance.
CooperCompanies (NYSE: COO) will announce its third quarter 2022 financial results on August 31, 2022, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss the results and other corporate developments. Participants can register for the call through a provided link and listen to a simultaneous webcast available on their website. Cooper, headquartered in San Ramon, CA, operates through CooperVision and CooperSurgical, employing over 12,000 people and selling products in more than 100 countries.
CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, payable on August 11, 2022, to stockholders of record on July 27, 2022. This move aligns with the company’s board-approved strategy to distribute annual dividends. CooperCompanies operates through CooperVision and CooperSurgical, focusing on vision care and women's health products, respectively. The company is headquartered in San Ramon, CA, and employs over 12,000 people globally, with sales in more than 100 countries.
CooperCompanies (NYSE: COO) reported a 15% year-over-year revenue increase to $829.8 million for its fiscal second quarter ending April 30, 2022. CooperVision revenue rose 6% to $553.8 million, while CooperSurgical surged 40% to $276.0 million. GAAP diluted EPS was $2.55, up $0.19, while non-GAAP diluted EPS fell 4% to $3.24. Operating margin decreased to 16% from 20% due to currency effects. The company updated fiscal 2022 revenue guidance to $3,280 - $3,312 million.
CooperVision has appointed Alex Wilkes as President of the Americas, effective June 14, 2022. Wilkes, with over a decade of experience in the eye care industry, previously served as Senior VP and GM of Pearle Vision at Luxottica. He will oversee growth strategies for the U.S., Canada, and Latin America. Mark Harty, EVP and Chief Commercial Officer, emphasized Wilkes' success in driving growth and market strategies. Wilkes expressed enthusiasm about joining CooperVision, aligning with its values and innovative product direction.
CooperCompanies (NYSE: COO) will participate in the Jefferies Healthcare Conference on June 9, 2022, at 1:00 PM ET. Al White, the President and CEO, will represent the company during this session.
The event can be accessed via CooperCompanies’ website, with a replay available 48 hours post-event. CooperCompanies is a global medical device firm operating through CooperVision and CooperSurgical, focusing on vision care and women's health products. Headquartered in San Ramon, CA, the company employs over 12,000 people and sells products in more than 100 countries.
CooperCompanies (NYSE: COO) has published its 2021 ESG Highlights Report, detailing ESG progress relevant to stakeholders. Highlights include a 100% score on the Human Rights Campaign’s Corporate Equality Index, gender parity on the Board, and 35% ethnic diversity in the workforce. Cooper became a participant in the UN Global Compact initiative.
CooperCompanies (NYSE: COO) announced that it and Cook Medical received a second request from the FTC regarding the acquisition of Cook Medical’s Reproductive Health business. This request, part of the HSR Act's regulatory process, extends the waiting period until compliance is achieved. The companies are collaborating with the FTC and anticipate closing the deal by the end of 2022.
Cooper operates two business units: CooperVision and CooperSurgical, focusing on medical devices and fertility solutions.
EssilorLuxottica and CooperCompanies have finalized their joint venture agreement for SightGlass Vision, focusing on innovative myopia management technologies. This collaboration aims to commercialize Diffusion Optics Technology™, which can potentially slow myopia progression in children by scattering light to reduce retinal contrast. With myopia affecting 2.6 billion globally, the partnership aims to enhance awareness and access to solutions. The lenses are not yet approved for sale in the U.S., marking an important step in addressing the rising myopia prevalence projected to impact half of the global population by 2050.
A recent peer-reviewed study published in Optometry and Vision Science confirms that CooperVision's MiSight® 1 day contact lenses effectively control myopia in children. The six-year trial shows that 90% of myopic children benefit from the lenses, with a sustained slowing of eye growth observed over time. The study reveals that treatment effects are particularly strong in younger and faster-progressing children. CooperVision reinforces its commitment to myopia management, aiming to provide effective solutions for vision care.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
